# The anti-viral protein Shiftless blocks p-body formation during KSHV infection

**Authors:** David Hatfield, William Rodriguez, Timothy Mehrmann, Mandy Muller

PMC · DOI: 10.1099/jgv.0.002229 · The Journal of General Virology · 2026-03-13

## TL;DR

This study shows that the protein Shiftless disrupts RNA processing bodies during KSHV infection, which helps block viral replication.

## Contribution

The study identifies a novel region in Shiftless responsible for disrupting P-bodies and links this activity to anti-viral defense.

## Key findings

- Shiftless restricts P-body formation even under oxidative stress.
- A specific region of Shiftless is necessary for P-body disruption and anti-viral activity.
- Disruption of P-bodies by Shiftless increases anti-viral cytokine expression.

## Abstract

Processing bodies (P-bodies/PBs) are non-membranous foci involved in coordinating RNA fate by regulating translation and mRNA decay. In this study, we characterize the anti-viral factor Shiftless (SHFL) as a potent disruptor of PB dynamics. We show SHFL expression restricts PB accumulation even in the context of oxidative stress, suggesting that SHFL expression impedes PB formation. Mutational approaches revealed that SHFL RNA-binding activity is not required to restrict PB formation. However, we have identified a new region of SHFL, a bridge between two distant SHFL domains, as necessary for SHFL-mediated PB disruption. Furthermore, we show that SHFL’s ability to disrupt PB formation also impacts its anti-viral activity during infection by the gammaherpesvirus Kaposi’s sarcoma-associated herpesvirus (KSHV). While WT SHFL efficiently restricts KSHV lytic reactivation, SHFL mutants defective in PB disruption no longer restrict KSHV reactivation. SHFL-mediated PB disruption also leads to increased expression of several anti-viral cytokines, further emphasizing the connection among SHFL, PB dynamics and the SHFL-dependent anti-viral state. Taken together, our observations suggest a role of SHFL in inhibiting PB formation to restrict KSHV lytic replication, reinforcing the importance of crosstalk between RNA fate and the innate immune response to viral infection.

## Linked entities

- **Proteins:** SHFL (shiftless antiviral inhibitor of ribosomal frameshifting)
- **Diseases:** Kaposi’s sarcoma (MONDO:0005055), KSHV (MONDO:0005055)

## Full-text entities

- **Genes:** CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, ATF3 (activating transcription factor 3) [NCBI Gene 467], SOX [NCBI Gene 4961512], TNRC6A (trinucleotide repeat containing adaptor 6A) [NCBI Gene 27327] {aka CAGH26, FAME6, GW1, GW182, TNRC6}, SHFL (shiftless antiviral inhibitor of ribosomal frameshifting) [NCBI Gene 55337] {aka C19orf66, IRAV, RyDEN, SFL}, RBFOX2 (RNA binding fox-1 homolog 2) [NCBI Gene 23543] {aka FOX2, Fox-2, HNRBP2, HRNBP2, RBM9, RTA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RNPC3 (RNA binding region (RNP1, RRM) containing 3) [NCBI Gene 55599] {aka CPHD7, IGHD5, RBM40, RNP, SNRNP65}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, KRT81 (keratin 81) [NCBI Gene 3887] {aka HB1, Hb-1, K81, KRTHB1, MLN137, MNLIX2}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}, AGO2 (argonaute RISC catalytic component 2) [NCBI Gene 27161] {aka CASC7, EIF2C2, LESKRES, LINC00980, PPD, Q10}, RBP4 (retinol binding protein 4) [NCBI Gene 5950] {aka MCOPCB10, RDCCAS}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, DDX6 (DEAD-box helicase 6) [NCBI Gene 1656] {aka HLR2, IDDILF, P54, RCK, Rck/p54}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}
- **Diseases:** herpesvirus infection (MESH:D006566), viral infection (MESH:D014777), KSHV infection (MESH:D012514), inflammatory (MESH:D007249), infected (MESH:D007239), coronavirus infection (MESH:D018352), tumorigenic (MESH:D002471)
- **Chemicals:** doxycycline (MESH:D004318), formaldehyde (MESH:D005557), PB (MESH:D007854), Tween 20 (MESH:D011136), NaCl (MESH:D012965), DTT (MESH:D004229), 4SU (-), PAN (MESH:C041728), Triton X-100 (MESH:D017830), RFP (MESH:D012293), NP-40 (MESH:C010615), sodium arsenite (MESH:C017947), paraformaldehyde (MESH:C003043), sodium citrate (MESH:D000077559), sodium butyrate (MESH:D020148), SDS (MESH:D012967), DAPI (MESH:C007293), TRIzol (MESH:C411644)
- **Species:** Gammacoronavirus (genus) [taxon 694013], Mus musculus (house mouse, species) [taxon 10090], Human gammaherpesvirus 8 (no rank) [taxon 37296], herpesvirus [taxon 39059], Homo sapiens (human, species) [taxon 9606], Orthonairovirus abuminaense (species) [taxon 2843618]
- **Mutations:** L264A, R131A, W191A, R136A, G259A, L269A, R133A, L261A, L267A
- **Cell lines:** iSLK.BAC16 — Homo sapiens (Human), Clear cell renal cell carcinoma, Cancer cell line (CVCL_B6YU), FLAG — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_C0IU), iSLK.219 — Homo sapiens (Human), Clear cell renal cell carcinoma, Cancer cell line (CVCL_B6YV), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12987661/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12987661/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12987661/full.md

---
Source: https://tomesphere.com/paper/PMC12987661